Maintenance therapy of gastroesophageal reflux disease patients with omeprazole.

奥美拉唑 医学 格尔德 内科学 回流 随机对照试验 胃肠病学 生活质量(医疗保健) 维持疗法 疾病 书呆子 前瞻性队列研究 外科 化疗 护理部
作者
Bojan Tepeš,Borut Štabuc,Borut Kocijancic,Marjan Ivanusa
出处
期刊:PubMed 卷期号:56 (89): 67-74 被引量:5
链接
标识
摘要

Gastroesophageal disease (GERD) is a chronic disease with an increasing prevalence. The purpose of this study was to establish the relationship between rate of relapses and maintenance therapy strategies in patients with gastroesophageal reflux disease.Two hundred sixteen patients were included in a prospective randomized study. Patients meeting the criteria for GERD and successfully completing acute therapy were included in the study. Patients with NERD and those with mild ERD (LA grade A and LA grade B) were randomly assigned to group A1 or A2. Group A1 patients were allocated to on-demand therapy with omeprazole 20 mg. Group A2 patients received continuous therapy with omeprazole 10 mg daily. Patients with ERD LA grade C and LA grade D were allocated to group B and treated with 20 mg of omeprazole daily. Clinical control visits were scheduled every three months. The last visit, at 12 months, included mandatory gastroscopy. In cases of suspected relapse, additional control visits and gastroscopy were done outside the regular schedule. GERD relapses and quality of life between different groups of patients were the primary outcome of the study.Of the total number of patients, 94 were allocated to group A1, 102 to group A2, and 20 to group B. In the per-protocol analysis, the cumulative relapse rate at 12 months was 34.9% (95% CI 24.6%-45.2%) in group A1, and 15.3% (95%, CI 7.6%-22.9%) in group A2 (p < 0.05), and 40% (intention to treat; 95% CI 18.55-61.5%) in group B. No statistically significant differences were found between the groups with regard to the health-related quality of life evaluation. None of the patients experienced serious adverse reactions during the study period.In patients without esophagitis or with esophagitis LA grade A at baseline, receiving 10 mg doses of omeprazole, a statistically significantly lower relapse rate was observed as compared to the patients with on-demand therapy. In patients with esophagitis LA grade B no differences in the relapse rate were found, without regard to the regimen used. Patients with esophagitis LA grade C and LA grade D had a high rate of relapse, often asymptomatic, despite therapy with 20 mg omeprazole.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
dddd发布了新的文献求助10
1秒前
ANNNNNN完成签到,获得积分10
1秒前
思源应助茨恩层采纳,获得10
2秒前
CipherSage应助口腔飞飞采纳,获得10
2秒前
2秒前
赖羊羊发布了新的文献求助10
2秒前
3秒前
3秒前
4秒前
酷波er应助wuxiaochen采纳,获得10
5秒前
yh发布了新的文献求助10
7秒前
movoandy发布了新的文献求助10
7秒前
zskyworth完成签到,获得积分10
7秒前
orechan完成签到 ,获得积分10
7秒前
8秒前
yxy发布了新的文献求助10
9秒前
9秒前
量子星尘发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
10秒前
11秒前
QL发布了新的文献求助10
11秒前
耍酷芹菜完成签到,获得积分10
12秒前
研友_n0gowL完成签到,获得积分10
13秒前
dawn发布了新的文献求助10
15秒前
神奇海螺完成签到,获得积分10
15秒前
口腔飞飞发布了新的文献求助10
15秒前
小圭韦发布了新的文献求助30
15秒前
16秒前
16秒前
16秒前
共享精神应助沉静的映秋采纳,获得10
16秒前
科研通AI5应助kkem采纳,获得10
17秒前
直率的彤完成签到,获得积分10
17秒前
OrangeWang完成签到,获得积分10
18秒前
18秒前
哈哈哈发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Social Work Ethics Casebook(2nd,Frederic G. R) 600
HEAT TRANSFER EQUIPMENT DESIGN Advanced Study Institute Book 500
Master Curve-Auswertungen und Untersuchung des Größeneffekts für C(T)-Proben - aktuelle Erkenntnisse zur Untersuchung des Master Curve Konzepts für ferritisches Gusseisen mit Kugelgraphit bei dynamischer Beanspruchung (Projekt MCGUSS) 500
A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels 500
Thomas Hobbes' Mechanical Conception of Nature 500
One Health Case Studies: Practical Applications of the Transdisciplinary Approach 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5112322
求助须知:如何正确求助?哪些是违规求助? 4320138
关于积分的说明 13461020
捐赠科研通 4151155
什么是DOI,文献DOI怎么找? 2274630
邀请新用户注册赠送积分活动 1276485
关于科研通互助平台的介绍 1214649